Latest news with #EchoIQ
News.com.au
08-07-2025
- Business
- News.com.au
EchoSolv enters Mayo's test zone as it chases FDA approval
EchoSolv enters Mayo's gauntlet for FDA nod Echo's AI flags heart failure before it hits the fan Other ASX stocks that have trialled with Mayo On July 1, Echo IQ released an announcement that made cardiologists sit a little straighter. The Sydney-based outfit said its heart-failure software, EchoSolv HF, has officially entered Mayo Clinic Platform's 'Validate' program. If you haven't bumped into that term before, Validate is Mayo's obstacle course. An independent crew takes your algorithm, runs it against mountains of data, and publishes a verdict on accuracy, bias and clinical usefulness. Pass the test and you've earned real bragging rights, plus the clean dossier the FDA likes to see attached to a 510(k) submission. 'We're excited to commence the study, which we believe will provide additional validation of the technology," said EchoIQ's CEO, Dustin Haines. "This marks the next step in our stated strategy to achieve FDA clearance for EchoSolv HF in the second half of this calendar year." So why the urgency? Because heart failure is America's priciest revolving door – US$60 billion a year in hospital readmissions and climbing. Echo IQ's plan is to slip EchoSolv into the echo review process, right when the report first lands, so at-risk patients can be flagged early and long before they boomerang back to emergency. Unlike image-heavy rivals, EchoSolv reads the echo report itself – 140-plus measurements captured during a standard scan – and spits out a risk score in under a minute. An echo by the way, is short for echocardiogram – a quick, painless ultrasound scan that turns sound waves into moving pictures and measurements of how your heart's pumping. With EchoSolv, US hospitals won't need new probes or hardware, just a browser tab and the existing reimbursement code 93799. Evolution Capital, which has slapped a 74-cent fair value on the stock (versus EIQ's current stock price of 24 cents ), points to an almost pristine AUC of 0.986 for EchoSolv-AS (the aortic stenosis version) in a Harvard study of more than 31,000 patients. AUC is 'area under curve', where 1 means perfect accuracy. That performance, plus an exclusive pipeline of 60 US hospitals on top of 41 early partners, gives Echo IQ a running start if the FDA thumbs-up lands on schedule, Evolution said. AI that sees heart failure coming EchoSolv HF takes the 140+ measurements already found in a standard echo report, runs them through a mixture-density neural network, and spits out a heart failure risk score in seconds. The AI technology was trained on more than a million echo studies from the National Echo Database of Australia. These records are linked to real patient outcomes, so the model learned to spot the early signs of heart failure based on how those patients actually fared. In two 2024 proof-of-concept trials, the AI tool picked up 86% of heart-failure cases compared to 46% with standard clinical review. When doctors added the AI's score to their own read, accuracy jumped to 97%. EchoSolv HF shares the same tech DNA as the EchoSolv-AS, which looks specifically for severe aortic stenosis – the valve-narrowing disease that can march quietly toward heart failure if surgeons don't intervene. EchoSolv-AS has already cleared the FDA, thanks to that near-perfect performance (AUC 0.986) in a Harvard Beth Israel validation of 31,000-plus patients. Who else Mayo has worked with Meanwhile, the Mayo badge matters because Mayo's data library is deep and its scepticism is legendary. It also has form for turbo-charging Aussie med-techs. Wind the clock back to 2016: ProMedicus (ASX:PME) inked an $18 million radiology-software deal with Mayo and set off on a nine-year share-price moonwalk. HeraMED (ASX:HMD) previously ran a fetalâ€'heartbeat study at Mayo's Minnesota campus, Noxopharm added Mayo sites to its CEPâ€'2 sarcoma trial in midâ€'2022. Optiscan (ASX:OIL) signed a Mayo coâ€'development deal on robotic breastâ€'cancer imaging last year. More recently, EMvision Medical Devices (ASX:EMV) 's bedside stroke scanner caught Mayo clinicians' eyes; the Florida campus is now part of its pivotal trial, and a De Novo submission is in the works. And now, EchoIQ said if all the planets line up, the FDA decision could arrive before Christmas trees go up. Of course, Stockhead is not suggesting these names will match the ProMedicus playbook, but Mayo's interest tends to be more than just polite curiosity. At Stockhead we tell it like it is. While EMVision is a Stockhead advertiser, it did not sponsor this article.
Yahoo
22-06-2025
- Business
- Yahoo
Pro Medicus And 2 Other High Growth Tech Stocks In Australia
In the current Australian market landscape, the ASX 200 futures are indicating a slight dip of -0.2% amid geopolitical tensions and mixed economic signals, while unemployment remains stable at 4.1%. Against this backdrop, high growth tech stocks like Pro Medicus are garnering attention for their potential to thrive in uncertain conditions by leveraging innovation and adaptability to navigate market challenges. Name Revenue Growth Earnings Growth Growth Rating Gratifii 42.14% 113.99% ★★★★★★ Pro Medicus 22.19% 23.49% ★★★★★★ WiseTech Global 20.15% 25.52% ★★★★★★ Wrkr 56.40% 116.83% ★★★★★★ AVA Risk Group 29.15% 108.15% ★★★★★★ Echo IQ 61.50% 65.86% ★★★★★★ BlinkLab 65.54% 64.35% ★★★★★★ Immutep 70.42% 42.39% ★★★★★☆ Adveritas 52.34% 88.83% ★★★★★★ SiteMinder 19.89% 69.58% ★★★★★☆ Click here to see the full list of 47 stocks from our ASX High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$28.92 billion. Operations: Pro Medicus Limited generates revenue primarily through the production of integrated software applications for the healthcare industry, totaling A$184.58 million. The company's operations span Australia, North America, and Europe, focusing on imaging software and radiology information systems for medical facilities. Pro Medicus, a standout in the Australian tech landscape, exemplifies robust growth with its revenue and earnings forecast to expand at 22.2% and 23.5% per annum respectively, significantly outpacing the broader market's expectations. This performance is bolstered by strategic share repurchases, with a recent buyback of 28,326 shares for AUD 6.35 million enhancing shareholder value. Additionally, inclusion in the S&P International 700 and Global 1200 indices not only underscores its market relevance but also augments its visibility among global investors. The company's commitment to innovation is evident from its R&D initiatives aimed at advancing healthcare technology solutions—a sector witnessing rapid growth due to increasing demand for efficient medical services. Navigate through the intricacies of Pro Medicus with our comprehensive health report here. Explore historical data to track Pro Medicus' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: SEEK Limited operates as an online employment marketplace service provider across Australia, South East Asia, New Zealand, the United Kingdom, Europe, and other international markets with a market cap of A$8.55 billion. Operations: The company generates revenue primarily through its employment marketplace services, with A$821.40 million from the ANZ region and A$240.90 million from Asia. Amidst a challenging landscape, SEEK has demonstrated resilience with its revenue and earnings poised for significant growth. Despite a substantial one-off loss of A$119.8 million last year, the company's revenue is expected to rise by 9.1% annually, outpacing the Australian market's growth of 5.6%. Furthermore, SEEK's earnings are forecasted to surge by 25.9% per year, notably higher than the market average of 11.6%. This robust financial outlook is underpinned by strategic initiatives and an Analyst/Investor Day that highlighted future prospects, reinforcing SEEK's potential in a competitive sector. Unlock comprehensive insights into our analysis of SEEK stock in this health report. Understand SEEK's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases, with a market cap of A$8.43 billion. Operations: Telix Pharmaceuticals generates revenue primarily from its Precision Medicine segment, which accounts for A$771.11 million, while its Therapeutics and Manufacturing Solutions segments contribute A$9.35 million and A$2.75 million, respectively. Telix Pharmaceuticals has demonstrated a robust trajectory in the high-growth tech sector, particularly through its innovative approaches in prostate cancer imaging. With a staggering annual earnings growth of 858% last year and an expected annual revenue increase of 19.8%, Telix outpaces the Australian market's average growth significantly. Recent strategic product launches, like the AlFluor™ platform and Illuccix®, have not only expanded its portfolio but also fortified its market position by enhancing diagnostic precision and treatment efficacy in oncology. These developments underscore Telix's commitment to advancing healthcare technology, positioning it well for sustained growth amidst evolving medical demands. Delve into the full analysis health report here for a deeper understanding of Telix Pharmaceuticals. Gain insights into Telix Pharmaceuticals' past trends and performance with our Past report. Click here to access our complete index of 47 ASX High Growth Tech and AI Stocks. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:PME ASX:SEK and ASX:TLX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
15-04-2025
- Business
- Yahoo
When Will Echo IQ Limited (ASX:EIQ) Breakeven?
We feel now is a pretty good time to analyse Echo IQ Limited's () business as it appears the company may be on the cusp of a considerable accomplishment. Echo IQ Limited provides artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia and the United Kingdom. The AU$168m market-cap company posted a loss in its most recent financial year of AU$5.4m and a latest trailing-twelve-month loss of AU$8.9m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Echo IQ's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Expectations from some of the Australian Software analysts is that Echo IQ is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of AU$1.1m in 2026. So, the company is predicted to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 111%, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected. Given this is a high-level overview, we won't go into details of Echo IQ's upcoming projects, though, take into account that by and large a high growth rate is not out of the ordinary, particularly when a company is in a period of investment. Check out our latest analysis for Echo IQ One thing we'd like to point out is that Echo IQ has no debt on its balance sheet, which is quite unusual for a cash-burning growth company, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company. This article is not intended to be a comprehensive analysis on Echo IQ, so if you are interested in understanding the company at a deeper level, take a look at Echo IQ's company page on Simply Wall St. We've also put together a list of key aspects you should further examine: Historical Track Record: What has Echo IQ's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Echo IQ's board and the CEO's background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
